Bicyclic heterocycle compounds methods of use thereof for the treatment of herpes viruses

A compound of structural formula (I):

• or a pharmaceutically acceptable salt thereof,
• wherein:
• A is a bond or —O—;
• X is —N— or —C(R2)—;
• Y is —N— or —C(R3)—, such that only one of X and Y can be —N—;
• Z is —N— or —C(R4)—;
• R1 is 5 to 7-membered monocyclic heterocycloalkyl or 9 or 10-membered bicyclic heterocycloalkyl, wherein said 5 to 7-membered monocyclic heterocycloalkyl group, and said 9 or 10-membered bicyclic heterocycloalkyl group can be optionally substituted with up to three RA groups, which can be the same or different, and wherein said 5 to 7-membered monocyclic heterocycloalkyl group, and said 9 or 10-membered bicyclic heterocycloalkyl group can optionally have a ring carbon atom functionalized as a carbonyl group;
• R2 is selected from H, C1-C6 alkyl, —O—(C1-C6 alkyl), C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, —CN, —NH2, —C(O)O—(C1-C6 alkyl), C3-C7 cycloalkyl, C4-C7 heterocycloalkyl, C6-C10 aryl, 5 to 7-membered monocyclic heteroaryl, and 9 or 10-membered bicyclic heteroaryl, wherein said C3-C7 cycloalkyl group, said C6-C10 aryl group, said 5 to 7-membered monocyclic heteroaryl group, and said 9 or 10-membered bicyclic heteroaryl group can be optionally substituted with up to three RB groups, which can be the same or different, or where R2 and R3, together with atoms to which they are attached, are joined to form a 5-membered heteroaryl group;
• R3 is selected from H, C1-C6 alkyl, C1-C6 hydroxyalkyl, 5 to 7-membered monocyclic heteroaryl, —O-(5 to 7-membered monocyclic heteroaryl), C3-C7 cycloalkyl, wherein said C3-C7 cycloalkyl group, and any of said 5 to 7-membered monocyclic heteroaryl groups, can be optionally substituted with up to three RC groups, which can be the same or different;
• R4 is selected from H, C1-C6 alkyl, C1-C6 hydroxyalkyl, and C3-C7 cycloalkyl;
• R5 is selected from H, C1-C6 alkyl, —OR7, —CN, —NH2, C1-C6 hydroxyalkyl, C1-C6 haloalkyl, —O—(C1-C6 hydroxyalkyl), —(C1-C6 alkylene)-NH—(C1-C6 haloalkyl), —O—(C1-C6 alkylene)m-(C3-C7 cycloalkyl), —O—(C1-C6 alkylene)m-(5 to 7-membered monocyclic heterocycloalkyl), and —(C1-C6 alkylene)m-(5 to 7-membered monocyclic heterocycloalkyl), wherein said C1-C6 alkyl group, said C3-C7 cycloalkyl group, and said 5 to 7-membered monocyclic heterocycloalkyl group can each be optionally substituted with one or more substituents, each independently selected from —OH, C1-C6 alkyl, and C3-C7 cycloalkyl, and wherein said C1-C6 haloalkyl can be optionally substituted with one —NH2 group;
• R6 represents up to 3 phenyl ring substituents, which can be the same or different, and are each independently selected from C1-C6 haloalkyl, C1-C6 hydroxyalkyl, —CN, —NO2, —OR7, and halo;
• each occurrence of R7 is independently selected from H, C1-C6 alkyl, and C3-C7 cycloalkyl;
• each occurrence of RA is independently selected from C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxyalkyl, 5 to 7-membered monocyclic heterocycloalkyl, —C(O)—(C1-C6 alkyl), and halo, wherein said 5 to 7-membered monocyclic heterocycloalkyl group can be optionally substituted with up to 3 substituents, which can be the same or different, and are each independently selected from C1-C6 alkyl, 5 to 7-membered monocyclic heterocycloalkyl, and halo;
• each occurrence of RB is independently selected from C1-C6 alkyl, C3-C7 cycloalkyl, —O—(C3-C7 cycloalkyl), —OR7, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, —O—(C1-C6 alkylene)m-(5 to 7-membered monocyclic heterocycloalkyl), and —(C1-C6 alkylene)m-(5 to 7-membered monocyclic heterocycloalkyl), and —NH2;
• each occurrence of RC is independently selected from C1-C6 alkyl, —OR7, C1-C6 haloalkyl, and 5 to 7-membered monocyclic heterocycloalkyl;
• and
• each occurrence of m is independently 0 or 1.